![]() | ![]() |
Formats:
|
||||||||||||||||
α-Latrotoxin and Its Receptors Yuri A. Ushkaryov, Division of Cell and Molecular Biology, Imperial College London, London, SW7 2AY, UK, Tel. +44 (0)20 7594 5237; Fax: +44 (0)20 7594 5207; e-mail: y.ushkaryov/at/imperial.ac.uk; The publisher's final edited version of this article is available at Handb Exp Pharmacol. See other articles in PMC that cite the published article.Abstract α-Latrotoxin (α-LTX) from black widow spider venom induces exhaustive release of neurotransmitters from vertebrate nerve terminals and endocrine cells. This 130-kDa protein has been employed for many years as a molecular tool to study exocytosis. However, its action is complex: in neurons, α-LTX induces massive secretion both in the presence of extracellular Ca2+ (Ca2+e) and in its absence; in endocrine cells, it usually requires Ca2+e. To use this toxin for further dissection of secretory mechanisms, one needs an in-depth understanding of its functions. One such function that explains some α-LTX effects is its ability to form cation-permeable channels in artificial lipid bilayers. The mechanism of α-LTX pore formation, revealed by cryo-electron microscopy, involves toxin assembly into homotetrameric complexes which harbour a central channel and can insert into lipid membranes. However, in biological membranes, α-LTX cannot exert its actions without binding to specific receptors of the plasma membrane. Three proteins with distinct structures have been found to bind α-LTX: neurexin Iα, latrophilin 1 and receptor-like protein tyrosine phosphatase σ. Upon binding a receptor, α-LTX forms channels permeable to cations and small molecules; the toxin may also activate the receptor. To distinguish between the pore- and receptor-mediated effects, and to study structure-function relationships in the toxin, α-LTX mutants have been used. At least one non-pore-forming α-LTX mutant can activate latrophilin, a G protein-coupled receptor, causing release of Ca2+ from intracellular stores. Latrophilin action still requires Ca2+e and may trigger transmitter secretion either by itself or by activating Ca2+-channels and/or inducing Ca2+ waves. These results reveal two Ca2+e-dependent mechanisms of α-LTX action (membrane pore formation and signalling via latrophilin), but how α-LTX triggers Ca2+e-independent neurotransmitter release still remains unexplained. Hypotheses for this action include direct interaction with intracellular components involved in exocytosis or the effects of α-LTX pores. Keywords: α-latrotoxin, exocytosis, neurexin, latrophilin, protein tyrosine phosphatase σ 1. α-LTX and release of neurotransmitters The notorious black widow spider (Latrodectus genus) and its venom, first studied by ancient Greeks (Aristotle 350 B.C.), entered the era of modern science in the 1930’s with the discovery of its proteinacious active principles (D’Amour et al. 1936) and, following the demonstration that it affects synaptic neurotransmitter release (Longenecker et al. 1970) and the isolation of toxic components (Frontali et al. 1976), gripped the attention of neurobiologists. It played a role in the debate leading to the Ca2+ (Augustine et al. 1987) and vesicular quantum (Ceccarelli and Hurlbut 1980) paradigms of neurotransmission. However, some details of α-LTX actions still remain mysterious, despite its widespread use as a stimulant of neurosecretion. The venom contains at least 86 unique proteins (Duan et al. 2006), including several homologous LTXs which play a role in its toxicity to insects and crustaceans (Grishin 1998), with only one, α-LTX, targeting vertebrates specifically; reviewed by Rosenthal and Meldolesi (1989). α-LTX is usually isolated from spider venom by conventional chromatography (Frontali et al. 1976; Tzeng et al. 1978), but to achieve homogeneity and remove contaminants (Volkova et al. 1995; Pescatori et al. 1995) that may endow the preparation with uncharacteristic properties (Umbach et al. 1998), preparative native electrophoresis should ideally be used (Ashton et al. 2000). 1.1. Target cells The toxin induces strong and sustained release of neurotransmitters and hormones from secretory cells capable of regulated exocytosis (Rosenthal et al. 1990). The effects of α-LTX on neurosecretion were first described on a cellular level in the 1970’s at frog neuromuscular junctions (NMJ) (Longenecker et al. 1970; Frontali et al. 1976), and later in mouse brain slices (Tzeng et al. 1978), in synaptosomes (isolated brain nerve terminals) from rat (Grasso et al. 1978), dog (Tzeng and Siekevitz 1979) and guinea pig (Nicholls et al. 1982), primary cerebellar granule cell cultures (Grasso and Mercanti-Ciotti 1993) and in hippocampal organotypic cultures (Capogna et al. 1996). In addition, catecholamine-secreting chromaffin cells (Picotti et al. 1982) and PC12 cell line (Robello et al. 1987), insulin-secreting pancreatic β-cells in primary or derived cell cultures (Lang et al. 1998), oxytocin- and vasopressin-secreting neurohypophysis cells (Hlubek et al. 2003) and luteinising hormone-secreting rat gonadotropes (Tse and Tse 1999) were also used to characterise the toxin’s effects on secretion from non-neuronal excitable cells. A secretory cell not sensitive to α-LTX still remains to be found. 1.2. Site and mode of action From the earliest description of toxin’s actions on neuronal systems, it emerged that α-LTX affects specifically the presynaptic element, from which it causes massive neurotransmitter release (e.g. Longenecker et al. 1970). The toxin has no major enzymatic activities (Frontali et al. 1976). Crucially, α-LTX has been discovered to create Ca2+-permeable channels in lipid bilayers (Finkelstein et al. 1976), and a large body of evidence shows that Ca2+ influx through membrane channels induced by α-LTX in the presynaptic membrane accounts for a major part of its effect. Pore formation occurs in all the biological systems mentioned above, but the features of α-LTX-triggered release cannot be fully explained by the toxin pore. The effect of α-LTX at NMJs is usually delayed and develops fully after ~10 min, although synaptosomes react much faster. It is detected electrophysiologically as an increase in the frequency of spontaneous miniature postsynaptic potentials at NMJs (Longenecker et al. 1970; Misler and Hurlbut 1979; Ceccarelli and Hurlbut 1980; Tsang et al. 2000) and excitatory or inhibitory postsynaptic currents at central synapses (Capogna et al. 1996). In addition, α-LTX affects action potential-evoked, synchronous release, and does this in a time-dependent manner: initially, it enhances evoked potentials, but eventually inhibits (Capogna et al. 1996) or blocks them (Longenecker et al. 1970; Hurlbut and Ceccarelli 1979; Liu and Misler 1998). Finally, when used in higher concentrations, α-LTX can cause morphological deformation and cell death, as reviewed by Sudhof (2001). However, the most surprising feature of the α-LTX-evoked secretion is that it can occur both in the presence and absence of Ca2+e. 1.3. Ca2+-independent release The ability of α-LTX to trigger neurotransmitter exocytosis in the absence of extracellular Ca2+ remains particularly interesting and inexplicable to the field (Longenecker et al. 1970; Ceccarelli et al. 1979; see also Sudhof (2001) and Ushkaryov et al. (2004) for review). This is clearly different from depolarisation-induced exocytosis, which is Ca2+-dependent, but not unlike the effect of hypertonic sucrose. The possibility that α-LTX-induced release involves an unknown, Ca2+-independent mechanism which may also occur during normal synaptic activity has provided the casus belli for many a quest for α-LTX structure and receptors that could trigger neurotransmission via intracellular mechanisms. In neurones, the Ca2+-independent secretion is restricted to small synaptic vesicles, as demonstrated by synaptosomal and NMJ experiments, where glutamate, GABA and acetylcholine are released in the absence of Ca2+, while catecholamines or peptides are not (Matteoli et al. 1988; Davletov et al. 1998; Khvotchev et al. 2000). Ca2+-independent release does not normally occur in endocrine cells (Grasso et al. 1980; Michelena et al. 1997; Silva et al. 2005), although in some cultured cells it does (Meldolesi et al. 1983; Lang et al. 1998; Tse and Tse 1999). The characteristics of Ca2+-independent release are peculiar: it requires the presence of divalent cations, such as Mg2+, which can be added or removed in succession, causing respective bouts of secretion or its cessation (Misler and Hurlbut 1979). In the absence of Mg2+, this release can be supported by slightly hypertonic sucrose, by itself insufficient to cause secretion (ibid.). The Ca2+-independent release can be blocked by millimolar La3+ (Rosenthal et al. 1990) or concanavalin A (Grasso et al. 1978; Boehm and Huck 1998). It may involve release of Ca2+ from mitochondria, as observed in peripheral (Tsang et al. 2000) and not central synapses (Adam-Vizi et al. 1993), but it is unclear if stored Ca2+i itself can trigger release. As Ca2+ is important for endocytosis, the sustained secretory activity in its absence eventually depletes NMJ terminals (Longenecker et al. 1970; Ceccarelli and Hurlbut 1980), but not synaptosomes (Watanabe and Meldolesi 1983), of all vesicles. Electrophysiological recordings at NMJs show that in the absence of Ca2+ α-LTX causes a large but slow rise in the frequency of spontaneous exocytotic events, which then slow down and cease altogether; bursts of miniatures are never observed. 1.4. Ca2+-dependent release In the presence of Ca2+e, α-LTX also causes a slow and large increase in the frequency of miniature events, overlaid by bursts of release (Ceccarelli et al. 1979). As in the absence of Ca2+, depletion of vesicles and block of exocytosis also occurs, but because vesicles are able to recycle for some time, the total number of quanta released is twice higher in Ca2+ than in its absence (Fesce et al. 1986; Auger and Marty 1997). It appears that the gradual rise and fall of the frequency of vesicle fusion events is a common feature of α-LTX-induced release both with and without Ca2+e, and that Ca2+ adds an extra component, increasing the total release. Influx of Ca2+ through α-LTX pores might explain Ca2+-dependent secretion, but not the bursts of miniatures. These may be due to Ca2+ waves caused by activation of phospholipase C (PLC) (Vicentini and Meldolesi 1984; Davletov et al. 1998) and release of intracellular Ca2+ (Ca2+i). In fact, U73122 (blocks PLC activation by G proteins), thapsigargin (depletes Ca2+ stores) and 2-APB (inhibits activation of Ca2+ stores) block α-LTX action (Davletov et al. 1998; Ashton et al. 2001; Capogna et al. 2003), implicating a G protein cascade in Ca2+-dependent toxin-induced release. 2. The structure of α-LTX To understanding and explaining the complex activities of α-LTX, its primary and three-dimensional (3D) structure has been thoroughly studied. 2.1. Sequence analysis α-LTX is synthesised as a 157 kDa polypeptide (Kiyatkin et al. 1990) (Figure 1A
The most striking feature of the α-LTX primary structure is a series of 22 ankyrin repeats that account for about two thirds of the sequence (Figure 1B α-LTX is a mostly hydrophilic protein that does not have a classical hydrophobic signal peptide or clear transmembrane regions (TMRs). The hydrophilic nature of α-LTX seemed for a long time at odds with its membrane insertion capabilities, but a study of its 3D structure (Orlova et al. 2000) shed light on this issue (Section 2.2). 2.2. Higher-order structures So far, crystallisation of α-LTX has not been reported. However, the toxin has been successfully studied by cryo-electron microscopy (cryo-EM) (Orlova et al. 2000), a method that allows visualisation of proteins instantly frozen in their native conformations. The size of the toxin tetramer (~520 kDa) proved ideal for this approach to reveal medium-resolution (14 Å) information, and even the dimer (~260 kDa) was reconstructed to below 20 Å resolution, revealing detailed information on the domain organisation of the toxin in its two oligomeric states (Orlova et al. 2000). 2.2.1. Domain structure of the monomer The 3D cryo-EM reconstructions of the α-LTX tetramer and dimer (Orlova et al. 2000) show that the monomer consists of three domains (Figure 1C Despite having a large number of ankyrin repeats (superseded only by the 24 repeats in ankyrin itself), α-LTX does not assume the monotonous arch-like shape so characteristic of proteins with multiple ankyrin repeats, such as the 12-repeat ankyrin fragment (Michaely et al. 2002), the human protein phosphatase HEAT (15 repeats), or the porcine ribonuclease inhibitor LRR (16 repeats) (Andrade et al. 2001). Instead, the ankyrin repeat-containing part of α-LTX is broken in several places and forms clearly delimited domains and sub-domains probably reflecting sequence divergence of some repeats and the functional specialisation of the sub-domains. 2.2.2. Quaternary structures Although some monomers have been observed by cryo-EM in EDTA-treated α-LTX, the toxin almost always exists as a stable dimer (Orlova et al. 2000; Ashton et al. 2001). In the asymmetric dimer, the two monomers are associated “head to tail” by tight multipoint contacts mediated by the “horizontal” parts of the bodies and by the sides of the head domains (arrowhead in Figure 1C Association of dimers, strongly catalysed by Mg2+, produces a cyclical structure (Figure 1C Above this, in the centre of the “bowl”, the four heads form a cylindrical assembly surrounding the channel (Figure 1C
The wings extend sideways from the body domains perpendicular to the central symmetry axis of the tetramer and could participate in the binding to some receptors (see Sections 2.3 and 4). They also seem to mediate homotypic interactions, causing tetramers to assemble into flat 2D crystals, often containing large numbers of tetramers (Lunev et al. 1991). These lattices could underlie the frequently described phenomenon of α-LTX channel clusterisation (Robello et al. 1987; Krasilnikov and Sabirov 1992; Filippov et al. 1994; Van Renterghem et al. 2000). 2.3. Recombinant α-LTX Detailed structure-function analysis of α-LTX is impossible without generating mutants. The difficulty inherent to this approach is to ensure proper folding of this large protein. Two groups relied on baculovirus expression and successfully purified active recombinant toxins. Ichtchenko et al. (1998) used two 8-histidine tags for purification, whereas Volynski et al. (1999, 2003) utilised a monoclonal antibody. Recently, active recombinant α-LTX has been generated using bacteria in which both thioredoxin reductase and glutathione reductase are inactivated to improve the formation of disulphide bonds in expressed proteins (Li et al. 2005). The toxin is expressed as a fusion with glutathione-S-transferase (GST), which is used for affinity purification of the recombinant toxin and can be subsequently removed by selective proteolysis. Considering the relative ease of generating recombinant proteins in bacteria, this approach will facilitate structure-function studies of α-LTX. Using these methods, several useful observations regarding the functions of the α-LTX domains have been made by analysing various mutants of recombinant toxin. These results are discussed in relevant sections below. 3. Membrane pore How the hydrophilic α-LTX inserts into lipid membranes and makes cation-permeable pores is not fully known, but an in-depth insight into the mechanisms of channel formation has been gained by combining cryo-EM, biochemical and biophysical studies with toxin mutagenesis. α-LTX pore formation consists of at least three steps: toxin tetramerisation, interaction with a specific cell-surface receptor and, finally, membrane insertion. Many experimental procedures can affect some of these steps and thereby prevent or assist channel formation. 3.1. Tetramerisation The tetrameric state of α-LTX is divalent cation-dependent. Accordingly, treatment with EDTA renders purified α-LTX mostly dimeric, while subsequent addition of millimolar Ca2+ or Mg2+ promptly restores tetramerisation (Ashton et al. 2000). This transition, requiring conformation changes (Orlova et al. 2000) and catalysed by divalent cations, may explain the dependence of α-LTX pore-mediated actions on Mg2+ (e.g. Misler and Hurlbut 1979). Tetramerisation can also be triggered by amphipathic molecules (Ashton et al. 2000), possibly membrane lipids. Interestingly, La3+ at a concentration higher than 100 μM also greatly reduces the number of tetramers (Ashton et al. 2001). In addition, this trivalent cation is able to block the channels of membrane-inserted tetramers (see Section 3.4.6), making La3+ useful in studying pore-independent toxin effects. The role of tetramerisation in toxin pore formation has been vividly illustrated by mutagenesis of α-LTX. In particular, Ichtchenko et al. (1998) have generated an interesting mutant (α-LTXN4C) that contains a four-amino acid insert between the N-terminal domain and the ankyrin repeats (Figure 1B 3.2. Receptor interaction Although α-LTX is able to insert into pure lipid membranes (Finkelstein et al. 1976), reconstituted receptors greatly enhance the rate of insertion (Scheer et al. 1986). Biological membranes seem even more refractive to the toxin: when cells do not possess α-LTX receptors, no pore formation can be detected (Hlubek et al. 2000; Van Renterghem et al. 2000; Volynski et al. 2000), whereas expression of exogenous receptors allows abundant α-LTX insertion and concomitant channel formation. Receptors, thus, confer specificity to the pore-mediated effects of α-LTX. It is not clear whether receptors are directly involved in membrane insertion, simply concentrate toxin near the membrane or organise membrane lipid domains to make them accessible to α-LTX. Importantly for some aspects of toxin-evoked secretion, interaction with one of the receptors, neurexin (NRX), is Ca2+-dependent, while interaction with the other two, latrophilin 1 (LPH1) and protein tyrosine phosphatase σ (PTPσ), is completely Ca2+-independent (see Section 4 for more details). The role of the structural domains of α-LTX in receptor interaction has been studied by mutagenesis. Ichtchenko et al. (1998) have generated three point-mutants by replacing conserved cysteines in the N-terminal domain (Figure 1B In another work, Li et al. (2005) have deleted the C-terminal ankyrin repeats 15 to 22, comprising the head and part of the body (Figure 1B 3.3. Membrane insertion The insertion of the α-LTX channel into black lipid membranes is unidirectional (Robello et al. 1984), suggesting that the toxin has evolved specialised domains to help it enter lipid bilayers. The direct observation of tetramers inserted into artificial lipid membrane (Orlova et al. 2000) indicates that the “bowl” formed by the body domains is immersed deeply in the lipid, while the wing domains remain splayed on, and slightly buried into, the extracellular surface of the bilayer, while the heads are exposed to the extracellular space (Figure 2 In addition to the presence of receptors, the ionic composition of buffer (Finkelstein et al. 1976) and the makeup of lipid bilayer (Robello et al. 1984) can influence the rate of α-LTX insertion into lipid membranes. It is possible that membrane microenvironment affects the insertion of a receptor-bound tetramer also in a physiological context. For example, at 0 °C, α-LTX binds to receptor-containing membranes, but it is not inserted (Khvotchev et al. 2000; Volynski et al. 2000). Another feature of α-LTX is that it co-purifies with a small protein, called LMWP (Volkova et al. 1995) or latrodectin (Pescatori et al. 1995). It does not affect the toxicity of α-LTX nor has secretory activity of its own (Volkova et al. 1995). However, when LMWP is removed (Ashton et al. 2000), the toxin becomes unable to form channels in artificial lipid bilayers, although its receptor-mediated permeation of biological membranes is unhindered (Volynski et al. 2000). It is tempting to speculate that LMWP helps wild-type α-LTX to penetrate lipid bilayers. To test this, recombinant toxins lacking LMWP need to be studied in pure lipid membranes. The receptor-aided insertion of α-LTX into biological membranes has been recently investigated using recombinant toxin N-terminally fused to GST and expressed in bacteria (Li et al. 2005). When, after purification, the GST moiety is removed, the resulting wild type recombinant α-LTX inserts into the plasma membrane and induces strong cation currents in tsA cells (HEK-293-derived) transfected with NRX Iα, whereas the GST-fused toxin is much less effective. As both the GST-free and GST-fused toxins bind well to the receptors (Li et al. 2005), it is clear that GST attached to the α-LTX N-terminus decreases the efficiency of toxin incorporation into membranes. However, despite its large size and hydrophilicity, GST does not block channel formation completely, indicating that when α-LTX inserts into the membrane, the wing does not need to penetrate the bilayer. This idea is further supported by the analysis of a series of α-LTX truncation mutants, lacking 1, 2, 3 or 8 C-terminal ankyrin repeats (Li et al. 2005). When tested in NRX Iα-transfected tsA cells, some of these constructs induce cation conductance, others completely lack this ability. As all these mutants possess unaltered N-terminal wing domains, the wing apparently does not participate in pore formation, while the structure of the C-terminal head is crucial for membrane insertion. This is consistent with the model of the membrane-inserted α-LTX tetramer in Figure 2 3.4. Features of the pore 3.4.1. Ion selectivity Once formed, the α-LTX channel only mediates cationic currents, probably because negatively charged acidic side chains line the channel (Finkelstein et al. 1976). Most significantly, the α-LTX channel is permeable to Ca2+ (Finkelstein et al. 1976; Krasil’nikov et al. 1982; Mironov et al. 1986), and it is this aspect of the α-LTX channel that is most often considered. However, this channel is not very selective, and Ba2+, Sr2+, Mg2+ as well as Li+, Cs+ and, importantly, Na+ and K+ currents are also carried by the channel (Krasil’nikov et al. 1982; Mironov et al. 1986). A detailed analysis of the permeability of α-LTX channels to cations and non-electrolytes (Mironov et al. 1986; Robello 1989; Krasilnikov and Sabirov 1992) postulates that the negatively charged selectivity filter of the channel is located close to the extracellular side of the membrane, fitting in with the hypothesis that the C-terminal head domains form the selectivity filter (see Section 2.2.2). This hypothesis finds additional confirmation in the features of the α-LTX truncation mutants described above (Section 3.3) (Li et al. 2005). These mutants have 1 to 8 ankyrin repeats removed from their C-termini and form cation channels of dramatically different conductivities. For example, α-LTxΔ1 mutant mediates an enormous conductance, by far exceeding that of wild type toxin. It is possible that the removal of the last ankyrin repeat lifts an obstruction for cation movements in the extracellular mouth of the channel. In contrast, α-LTxΔ2 and α-LTxΔ3 make very inefficient channels, probably due to perturbations of the channel lining. Finally, α-LTxΔ8 does not induce any cation currents, as it seemingly cannot form tetramers. 3.4.2. Ca2+ currents Although Ca2+ only carries a small proportion of currents through cell membrane-inserted α-LTX channels (Hurlbut et al. 1994; Tse and Tse 1999), the influx of Ca2+ through presynaptically-targeted α-LTX channels is most often referred to, because of the well-established link between presynaptic [Ca2+] and neurotransmitter release. There is a wealth of evidence indicating that in conditions favourable to channel formation (e.g. in the presence of divalent cations), influx of extracellular Ca2+ through α-LTX channels is an important aspect of α-LTX action. Increases in [Ca2+]i upon α-LTX addition in the presence of Ca2+e have been detected in synaptosomes (Nicholls et al. 1982; Meldolesi et al. 1984), native PC12 (Grasso et al. 1980; Meldolesi et al. 1984) and chromaffin (Barnett et al. 1996) cells as well as in receptor-transfected COS (Volynski et al. 2000; Ashton et al. 2001), BHK (Krasnoperov et al. 1997) and neuroblastoma cells (Volynski et al. 2004). While the bulk of this effect is due to calcium influx through the toxin channel, it is possible that the rise in [Ca2+]i is contributes to by Ca2+ release from intracellular stores (Tse and Tse 1999; Tsang et al. 2000; Liu et al. 2005) or influx through endogenous Ca2+ channels (Nicholls et al. 1982; Lajus et al. 2006). In LPH-transfected neuroblastoma cells, Ca2+i waves caused by LPH signalling are observed in response to non-pore forming α-LTX (Volynski et al. 2004). Nevertheless, influx of Ca2+ through the channel formed by wild type toxin appears more dramatic. 3.4.3. Na+ currents α-LTX channels inserted in artificial membranes are permeable to Na+ (Krasil’nikov et al. 1982; Robello et al. 1984), which is modulated by Ca2+ added to the topologically extracellular side of the bilayer (Mironov et al. 1986). Inward Na+ currents are observed electrophysiologically in Xenopus oocytes, PC12 and neuroblastoma cells (Wanke et al. 1986; Filippov et al. 1994; Hurlbut et al. 1994), and α-LTX elevates [Na+i] in synaptosomes detectable with a fluorescent dye (Deri and Adam-Vizi 1993), although not with radioactive Na+ (Storchak et al. 1994). Such currents probably account for at least one of α-LTX actions: tetrodotoxin-insensitive depolarisation of artificial and biological membranes (Grasso and Senni 1979; Nicholls et al. 1982; Scheer et al. 1986). Although depolarisation could cause neurotransmitter release by activating voltage-gated Ca2+ channels, Ca2+ flow through the α-LTX channel probably overwhelms this effect (Nicholls et al. 1982), so the role of depolarisation in α-LTX action is unclear. In addition, Na+ currents through α-LTX channels can underlie some of the α-LTX-induced non-vesicular neurotransmitter release by causing, for example, the collapse of the cross-membrane Na+ gradient and the reversal of some (McMahon et al. 1990) but not all (Deri and Adam-Vizi 1993) transmitter uptake pumps. α-LTX-mediated Na+ influx can also induce mitochondria of frog NMJ synapses (Tsang et al. 2000) and neurohypophysis terminals (Hlubek et al. 2003) to release large amounts of Ca2+ into the cytosol because of the reversal of their Na+/Ca2+ exchangers, although this seems to be inconsequential for secretion in the absence of Ca2+e. In contrast, increases in [Ca2+]i, partially dependent on Na+e, correlate with acetylcholine release in synaptosomes (Deri and Adam-Vizi 1993). Generally, a rise [Na+]i in nerve terminals correlates with enhanced secretion (Meiri et al. 1981). Thus, Na+ currents represent yet another facet of the α-LTX channel actions at the synapse and could account for some of the toxin-evoked Ca2+e-independent vesicular release. However, α-LTX may be able to induced release even in Ca2+-free and Na+-free medium in synaptosomes (Storchak et al. 1994) and frog NMJs (Tsang et al. 2000). 3.4.4. Factors affecting conductance A perplexing feature of the literature that explores α-LTX channels is the extremely wide range of single-channel conductances, ranging from 15 pS (Wanke et al. 1986; Krasilnikov and Sabirov 1992) to 100-300 pS (Finkelstein et al. 1976; Van Renterghem et al. 2000) or even 1100 pS (Krasilnikov and Sabirov 1992). To put these figures in perspective, the voltage-gated K+ channel Kv1.2 and the ryanodine-sensitive Ca2+-release channels have conductances of 14-18 pS and ~700 pS, respectively (Lindsay et al. 1994; Gutman et al. 2005) (Figure 2 Several plausible hypotheses can explain this variability. Firstly, the venom contains a range of pore-forming toxins with varying conductances. Secondly, there is evidence that the make-up of the permeated membrane (Robello et al. 1984; Scheer et al. 1986; Krasilnikov and Sabirov 1992) and variations in lipid packing and order (Chanturia and Lishko 1992), but not the type of receptor present (Hlubek et al. 2000; Van Renterghem et al. 2000), can affect the properties of α-LTX channels. Interestingly, Ca2+ inhibits the conductance of α-LTX channels to monovalent cations, causing a “flickery block”, in artificial membranes (Mironov et al. 1986; Krasil’nikov et al. 1988), neuroblastoma cells (Hurlbut et al. 1994) and embryonic kidney cells (Hlubek et al. 2000), although this is not apparent in receptor-expressing oocytes (Filippov et al. 1994). Mg2+ positively modulates the conductivity of toxin channel for Ca2+ (Davletov et al. 1998; Van Renterghem et al. 2000). Finally, the frequent observation of bursts of conductance, likely corresponding to synchronised opening and closing events, has led many authors to suggest that α-LTX channels form clusters in the membrane (Robello et al. 1987; Krasilnikov and Sabirov 1992; Filippov et al. 1994; Van Renterghem et al. 2000). Such clustering is plausible from a structural point of view, as crystalline arrays of α-LTX tetramers are observed by EM (Lunev et al. 1991) (see Section 2.2.2), and it may account for some of the variability in conductances reported in the literature. 3.4.5. Gating The channel is open most of the time, with an open probability of 0.8 (Filippov et al. 1994). Closure events, albeit rare, have been observed in many systems (Finkelstein et al. 1976; Wanke et al. 1986; Hurlbut et al. 1994), and several channels can open and close in concert (Krasilnikov and Sabirov 1992; Filippov et al. 1994; Tse and Tse 1999). Membrane depolarisation may increase the likelihood of closure events (Filippov et al. 1994; Van Renterghem et al. 2000), and Ca2+ and Mg2+ modulate gating (Filippov et al. 1994; Hurlbut et al. 1994). The molecular basis of gating is currently unknown, but is likely to involve head domains. 3.4.6. Divalent and trivalent cations The α-LTX pore is permeable to alkaline earth cations, whose affinities for the channel decrease in the following sequence: Mg2+ > Ca2+ > Sr2+ ≥ Ba2+ (Mironov et al. 1986). Transition metal cations (Cd2+ > Co2+ ≥ Ni2+ ≥ Zn2+ > Mn2+) strongly block Ca2+ and K+ currents through α-LTX channels in artificial membranes (Mironov et al. 1986). This block is only effective when the cation is applied from the cis-side (equivalent to the extracellular side) of the membrane. Millimolar concentrations of trivalent cations, such as Yb3+, Gd3+, Y3+, La3+ and Al3+, block the pore-mediated effects of α-LTX in synaptosomes (Scheer 1989). The nature of this effect is complex. For example, Al3+ blocks the binding of α-LTX to synaptosomes (Scheer 1989), while La3+ prevents tetramerisation (Ashton et al. 2000) and thereby channel insertion and formation. Most trivalent cations, at 50-100 μM, block previously inserted channels (Scheer 1989; Hurlbut et al. 1994; Van Renterghem et al. 2000) and inhibit α-LTX-mediated Ca2+-uptake, while La3+ blocks depolarisation as well (Scheer 1989). Channel inhibition by trivalent cations is very important because La3+ is essentially the only reagent that blocks the Ca2+-independent α-LTX-evoked neurotransmitter secretion in neurons (Scheer 1989; Capogna et al. 2003). The use of trivalent cations for the purpose of dissecting the mechanisms of α-LTX action, however, is complicated by their well-described ability to trigger neurotransmitter release in the absence of other stimuli (Scheer 1989). Furthermore, at low concentrations, both La3+ (at 15 μM) and Cd2+ (at 50 μM) support, rather than block, the secretagogue activity of the toxin (Misler and Falke 1987). 3.4.7. Permeation of molecules/leakage It is possible that the water-filled α-LTX channel, which is relatively wide (~10 Å at its narrowest (Krasilnikov and Sabirov 1992; Orlova et al. 2000), can pass small molecules. Indeed, α-LTX channels inserted in the membranes of synaptosomes, NMJ nerve terminals and receptor-transfected COS7 cells appear to pass fluorescein (Stokes-Einstein radius, Re = 4.5 Å) and norepinephrine (Re ≤ 4 Å) (Davletov et al. 1998; Rahman et al. 1999; Volynski et al. 2000), shown in Figure 2 These observations are particularly relevant to the experimental use of α-LTX in neurotransmission studies, since α-LTX has been shown in several systems to cause non-vesicular release by allowing leakage of cytoplasmic neurotransmitters (McMahon et al. 1990; Deri et al. 1993; Davletov et al. 1998). This flux could be mediated by the α-LTX channel itself, by local disruptions of cellular membranes, or by reversal of transmitter uptake pumps driven by Na+ gradient (see Section 3.4.3). Synaptosomes seem to be particularly sensitive to an increase in hydrostatic pressure, which may occur when influx of Na+ or Ca2+ leads to a concomitant influx of water. 3.5. Can the pore explain everything? It is now universally accepted that α-LTX can insert into, and permeabilise, artificial and biological membranes. Cation currents can explain some, but not all, of the toxin’s effects. For example, it is not clear how the α-LTX channel could mediate Ca2+e-independent exocytosis in neurons. Although it would be tempting to assign some of α-LTX actions in the absence of Ca2+e to Na+ currents, lack of Na+ does not prevent Ca2+-independent secretion (Tsang et al. 2000). Cation flux-associated incursion of terminals by water could be involved, but α-LTX effect on intracellular osmotic pressure has not been characterised yet. Based on the results of α-LTX mutagenesis, strong correlation exists between pore formation and stimulation of Ca2+-dependent exocytosis from neuroendocrine cells. However, in some experiments with chromaffin cells, α-LTX action does not involve Ca2+ entry (Michelena et al. 1997). In addition, α-LTX sensitises chromaffin cells to Ca2+ even when the cells are permeabilised and toxin pores should have no effect; this involves protein kinase C (PKC) activation (Bittner and Holz 2000). Furthermore, the ability of α-LTXN4C to induce Ca2+-dependent exocytosis without forming pores implicates a stimulating mechanism other than pore formation. Therefore, α-LTX receptors, which are so crucial for the toxin’s action in all biological systems, have been comprehensively studied. 4. Receptors The three currently known receptors for α-LTX - NRX, LPH (or CIRL) and PTPσ - were all isolated from brain extracts by affinity chromatography on immobilised α-LTX (Petrenko et al. 1990; Davletov et al. 1996; Krasnoperov et al. 1996; Krasnoperov et al. 2002a). Surprisingly, they were purified only as a result of three separate efforts several years apart. In part, this piecemeal discovery of α-LTX receptors reflects differences in purification procedures; in part, it is due to the researchers’ inability to explain all the actions of the toxin by the features of each newly found receptor, warranting further attempts at isolating the “ultimate” target of α-LTX. While new proteins interacting weakly/transiently with the toxin and mediating some of its activities may still be found, there is no doubt that NRX Iα, LPH1 and PTPσ exhaust the repertoire of major α-LTX receptors. As these proteins are discussed in detail below, it is important to remember that, with any receptor, wild-type α-LTX can insert into the membrane and form pores (or engage in other interactions), causing strong direct effects that make definitive conclusions regarding receptor signalling, or lack of it, difficult. Only when membrane insertion and pore formation are blocked (as, for example, in α-LTXN4C mutant, see 2.3), can the observed effects be attributed to the action of one or the other receptor. 4.1. Neurexin The first α-LTX receptor to be identified was isolated from solubilised bovine brain by toxin-affinity chromatography in the presence of Ca2+ (Petrenko et al. 1990) and termed neurexin (NRX) (Ushkaryov et al. 1992) (Figure 3
4.1.1. Structure NRX is a member of a family of polymorphous neuronal cell-surface receptors (Ushkaryov et al. 1992; Ushkaryov and Sudhof 1993; Ullrich et al. 1995) (Figure 3A All NRXs have a single transmembrane region (TMR) and a short cytoplasmic tail. In α-NRXs, the large ectodomains are composed of six LNS domains (Figure 3A 4.1.2. Distribution NRXs are present mostly in brain (Ushkaryov et al. 1992) but also in pancreas and lung (Occhi et al. 2002). They are differentially expressed in brain regions, showing partially overlapping patterns of distribution of their six main forms and region-specific splice variants (Ullrich et al. 1995). It is difficult to localise NRX proteins at the cellular level, partly because the respective α- and β-forms are almost identical immunologically. As demonstrated by light microscopy, NRXs are expressed at synapses (Ushkaryov et al. 1992; Dean et al. 2003), but in the absence of EM data, their distribution between the pre- and postsynaptic membranes is not clear. Based on the presynaptic action of α-LTX, NRX Iα is implicitly presynaptic; β-NRXs are assigned to presynaptic membranes due to their interaction with neuroligins, indeed localised in the postsynaptic membrane by EM (Song et al. 1999). It remains to be seen whether any NRXs may be expressed postsynaptically. 4.1.3. Binding of α-LTX Analysis of NRX isolated from brain by α-LTX-affinity chromatography (Petrenko et al. 1990; Petrenko et al. 1993) shows that out of the six main isoforms only NRX Iα binds toxin with sufficient affinity (Davletov et al. 1995), and this interaction strictly requires Ca2+ (Petrenko et al. 1990; Davletov et al. 1995). The α-LTX binding site has not been mapped in a systematic effort, but incidental evidence implicates the third major repeat, LNS(A3/B3). In particular, α-LTX binds neither a NRX Iα mutant lacking the LNS-domains B2, A3 and B3, nor the full-size NRX Iα with an insert in LNS(B3) (Davletov et al. 1995). Although LNS(B3) domains of all three β-NRXs are able to interact with α-LTX in a splicing-dependent manner under mild conditions (Sugita et al. 1999), they are not sufficient for strong toxin binding: NRX Iβ does not pull down α-LTX (Davletov et al. 1995), nor are β-NRXs isolated from brain by α-LTX chromatography (Petrenko et al. 1990). Finally, a NRX Iα mutant, containing only LNS(A3/B3), binds the toxin well (Li et al. 2005). Thus, the strong interaction of α-LTX with NRX Iα is mediated by both LNS(A3) and LNS(B3), while splicing in LNS(B3) regulates this binding. 4.1.4. Proposed functions The structure of NRXs is consistent with a function in cell adhesion and/or ligand binding. Indeed, the extracellular domains of α-NRXs interact specifically and strongly with neurexophilins (Petrenko et al. 1993; Petrenko et al. 1996; Missler et al. 1998b), a family of glycosylated, proteolytically processed hormone-like 30-kDa proteins with species-specific differential expression in mammalian tissues (Petrenko et al. 1996; Missler and Sudhof 1998). The biological role of neurexophilins is unknown (Missler et al. 1998b), but their tight binding to the LNS(B1) domain of α-NRXs implies long-term/structural, rather than short-term/signalling, interactions. In addition, both α- and β-NRXs can interact with neuroligins, a family of neuronal proteins that contain a region of homology to esterases in their extracellular domains and a single TMR (Ichtchenko et al. 1995; Ichtchenko et al. 1996) (Nguyen and Sudhof 1997; Boucard et al. 2005). Neuroligin-1 has been identified owing to its ability to bind all three β-NRXs - only if they lack an insert at splice site 4 (Ichtchenko et al. 1995) (Figure 3 In the cytoplasmic tail of NRXs, there is a short C-terminal site that binds to PDZ domain-containing scaffold proteins, CASK (Hata et al. 1996) and Mint (Biederer and Sudhof 2000). These proteins interact with each other and with Ca2+ channels; Mint also makes complexes munc18, a protein involved in vesicle exocytosis (Verhage et al. 2000). Therefore, NRXs may participate in arranging transmitter release mechanisms. Indeed, knockout of all three α-NRXs has demonstrated that they play a role in organising N- and P/Q-type Ca2+ channels (Zhang et al. 2005) in nerve terminals (Missler et al. 2003) and endocrine cells (Dudanova et al. 2006). Even though β-NRXs have the same C-terminal sequences as the respective α-NRXs, the two isoforms participate differently in synaptogenesis and transmitter secretion. In particular, α-NRXs are apparently not involved in synapse formation (Missler et al. 2003) but may influence the expression of postsynaptic NMDA (but not AMPA) glutamate receptors (Kattenstroth et al. 2004). 4.2. Latrophilin Because NRX Iα requires Ca2+ to bind α-LTX, it cannot mediate the toxin’s effects in the absence of Ca2+. The quest for a Ca2+-independent receptor continued, and a major protein was eventually isolated by α-LTX-chromatography of solubilised brain proteins and termed latrophilin (LPH) (Figure 4
4.2.1. Structure LPH is a large (185 kDa) heptahelical receptor. It comprises three major domains (Figure 4A Based on this homology and on the length of ectodomains, LPH and similar receptors have been initially classified as “Long N-terminus group B” GPCRs (Hayflick 2000; Stacey et al. 2000). However, it is recognised now (Fredriksson and Schioth 2005) that they form a separate group, termed “adhesion GPCRs”. This nomenclature stems from the fact that these receptors contain various cell adhesion modules in their ectodomains. The group includes 33 proteins identified by their function/activity or through genome searches (Fredriksson and Schioth 2005). LPH has two very similar homologues, LPH2 and LPH3 (Matsushita et al. 1999). The family is also called CIRL1-3 (Ichtchenko et al. 1999) and CL1-3 (an abbreviation combining the two other names of the protein, CIRL and LPH) (Sugita et al. 1998). The LPHs have seven sites of alternative splicing (Sugita et al. 1998; Matsushita et al. 1999). Some splice variants encode receptors with an altered third cytoplasmic loop or a truncated cytoplasmic tail (Matsushita et al. 1999), modifications that are likely to affect coupling to G proteins. 4.2.2. Unusual architecture “Adhesion GPCRs” have an unusual architecture (Gray et al. 1996; Krasnoperov et al. 1997; Volynski et al. 2004). They contain two functional parts: an N-terminal cell adhesion receptor-like extracellular domain and a C-terminal domain with seven TMRs and a signalling potential (Hayflick 2000; Stacey et al. 2000). Intriguingly, all these receptors are post-translationally cleaved at the GPS domain (Krasnoperov et al. 1997) (Figure 4A, B The peculiar biology of LPH has been studied in neuroblastoma cells stably expressing recombinant LPH1 (Volynski et al. 2004). Following delivery to the plasma membrane, the two receptor fragments can dissociate and behave as independent cell-surface proteins. However, under certain conditions, the fragments re-associate. This re-assembly, mediated only by seven most N-terminal amino acids of the CTF, is induced by detergents and also by α-LTX binding to the NTF (ibid.). Ternary α-LTX-NTF-CTF complexes form large patches in the plasma membrane, triggering formation of molecular dimers of the CTF. This process temporally and spatially correlates with signal transduction, which can be visualised using the non-pore-forming mutant α-LTXN4C (see Section 2.3). This signalling requires the full-size CTF and involves activation of PLC and release of Ca2+ from intracellular stores (ibid.). It is interesting that both in this model system and in central synapses (Ashton et al. 2001; Capogna et al. 2003), α-LTXN4C induces Ca2+ signals only in the presence of Ca2+e. Calcium ions may serve here as a co-factor for LPH activation or they may enter the cytosol through an LPH-activated Ca2+ channel(s). 4.2.3. Distribution LPHs are differentially distributed in mammalian tissues: while LPH1 and LPH3 are enriched in brain, LPH2 features more prominently in other tissues (Sugita et al. 1998; Ichtchenko et al. 1999; Matsushita et al. 1999). Similar to NRX Iα (Ushkaryov et al. 1992; Occhi et al. 2002), very small levels of LPH1 mRNA can be detected outside brain, especially in kidneys and pancreas, and both receptors reside in endocrine cells, such as pancreatic β-cells (Lang et al. 1998). Based on α-LTX binding and action, which are dramatically inhibited by the LPH gene knockout, this receptor is localised in presynaptic terminals. In a yeast two-hybrid system, the C-terminal cytoplasmic tail of LPH can bind Shank (Tobaben et al. 2000; Kreienkamp et al. 2000), an ankyrin repeat-containing protein of postsynaptic density, although the specificity and significance of this interaction is unclear. 4.2.4. Binding of α-LTX LPH1 has a very high affinity for α-LTX (Kd ~0.1-1.5 nM) (Volynski et al. 2000; Ichtchenko et al. 1999), while the interaction of LPH 2 with toxin is more than 10-fold weaker (Ichtchenko et al. 1999). α-LTX binds the Stalk/GPS domains of the NTF (Krasnoperov et al. 1999), while the lectin and olfactomedin regions upstream could participate in adhesion interactions with the extracellular matrix or adjacent cells (Figure 4B 4.2.5. Proposed functions The functions of LPH remain to be elucidated. As follows from the results of LPH1 gene knockout (Tobaben et al. 2002), this receptor is not crucial for basic neuronal survival and activity, although LPH2 and 3 may compensate for the lack of LPH1. The structure of all adhesion GPCRs indicates that these receptors can transform extracellular interactions into intracellular signalling. Being involved in some pathways leading to release of stored Ca2+, LPH may participate in the cell contact-dependent fine tuning of Ca2+i levels and modulation of transmitter secretion. 4.3. Protein tyrosine phosphatase σ In the search for a Ca2+ independent α-LTX receptor, affinity chromatography in the absence of Ca2+ was used to isolate brain proteins with any affinity for α-LTX. Sequencing of all proteins in the α-LTX column eluate (Krasnoperov et al. 1996; Krasnoperov et al. 2002b) has revealed that, in addition to LPH1, PTPσ can also bind to the column as a set of two minor bands. 4.3.1. Structure PTPσ is a member of the family of receptor-like PTPs that contain cell adhesion molecule-like extracellular domains, a single TMR and cytoplasmic phosphatase domains (Tonks 2006). In PTPσ, the extracellular domain comprises three immunoglobulin-like modules and, depending on alternative splicing, from four to eight fibronectin type III-like domains (Figure 5A
Reminiscent of LPH, PTPσ is proteolytically cleaved 125 residues upstream of the TMR into two fragments, which remain non-covalently associated (Figure 5A 4.3.2. Distribution The large splice variant of PTPσ is found in most tissues, while the shorter variant is mostly brain-specific (Yan et al. 1993; Pulido et al. 1995) but, similar to NRX Iα and LPH1, is also found in small amounts in some other tissues (Yan et al. 1993), which may be due to autonomic innervation. 4.3.3. Binding of α-LTX Despite the very low binding of this protein to toxin columns, the α-LTX-PTPσ interaction is specific and maps onto the fibronectin domains 2 and 3 (Krasnoperov et al. 2002b). These are present in both PTPσ1 and PTPσ2, but on over-expression of these splice variants in pancreatic β-cells, only PTPσ1 mediates the secretory action of α-LTX (Lajus and Lang 2006). This may be because the toxin binds PTPσ2 too far from the membrane and is then unable to insert into the plasma membrane. 4.3.4. Proposed functions As phosphorylation of proteins localised in focal adhesions controls cell-cell and cell-matrix interactions, dephosphorylation is also important for the regulation of cell adhesion. Indeed, PTPσ is involved in negative regulation of axonal growth (McLean et al. 2002; Thompson et al. 2003) and growth cone pathfinding (Meathrel et al. 2002). Apart from EGFR (see 4.3.1), PTPσ interacts with N-cadherin and dephosphorylates it, augmenting its catenin-mediated attachment to the cytoskeleton and inhibiting axonal growth (Figure 5B The structure of PTPσ is consistent with its role in binding ligands on the surface of other cells or in the extracellular matrix. It interacts with heparin sulphate proteoglycan in the basement membrane (Sajnani-Perez et al. 2003). It may also bind to the C-terminal domain of cell surface-exposed nucleolin, a normally nuclear protein that is presented on the surface of developing muscle cells (Alete et al. 2006). However, these complexes seem to mediate structural or long-term regulatory interactions rather than short-term signalling to the neuronal secretory machinery. 4.4. α-LTX receptors and signalling 4.4.1. NRX Iα Can NRXs transduce intracellular an exocytotic signal? All currently known cytoplasmic interactions of α- and β-NRXs appear to be stable, non-enzymatic, structural connections that are essential for neuronal development, synapse organisation and long-term regulation but are unlikely to underlie a massive and relatively fast response induced by α-LTX. However, toxin binding to NRXs might cause conformational changes in Mint, which, by interacting with munc18, might regulate the availability of docking sites for synaptic vesicles. On the other hand, even a truncated NRX Iα that lacks the cytoplasmic tail can mediate the sensitivity of PC12 cells to wild-type α-LTX (Sugita et al. 1999). The most likely explanation of this is that toxin inserts into the membrane on binding any membrane-attached form of NRX Iα (Volynski et al. 2000; Hlubek et al. 2000), and because NRX experiments require Ca2+e, influx of this cation through the toxin pore can trigger maximal exocytosis irrespective of any NRX Iα-mediated signalling. With this in mind, there is no doubt that NRXs (full-size or C-terminally truncated) constitute functional receptors for α-LTX (Sugita et al. 1999), but only in the sense that they provide binding sites for the toxin, which subsequently exerts its own actions. 4.4.2. LPH1 LPH1 is the only receptor capable of G-protein-mediated signalling induced by α-LTX in central synapses (Davletov et al. 1998; Ashton et al. 2001; Section 1.4). Furthermore, LPH1 is directly involved in α-LTXN4C-induced signalling in LPH-transfected neuroblastoma cells (Volynski et al. 2004). This mutant activates PLC also in neurons, causing release of Ca2+i (Ashton et al. 2001; Volynski et al. 2003; Volynski et al. 2004) and leading to neurotransmitter release, which is blocked when the Gq cascade is inhibited by various drugs (Davletov et al. 1998; Ashton et al. 2001; Capogna et al. 2003). LPH1 also co-purifies with Gq (Rahman et al. 1999). The endogenous ligand of LPH1 is currently unknown, and it is interesting to consider an invertebrate LPH orthologue from C. elegans (Mee et al. 2004; Willson et al. 2004). The nematode protein LAT-1 (B0457.1) lacks the olfactomedin region but contains the domains required for α-LTX binding (HRM, Stalk and GPS). Although its identity to vertebrate LPH1 is not too high (18-45 % in the area of toxin binding), it mediates the lethal effect of an α-LTX homologue, ε-latroinsectotoxin (Mee et al. 2004). C. elegans also expresses NRX and PTPσ homologues, but only the knockdown of LPH renders the worms resistant to ε-latroinsectotoxin (Mee et al. 2004). Interestingly, the worm LPH mediates the action of the anthelmintic octadepsipeptide emodepside, which causes paralysis in nematodes (Willson et al. 2004). By the coupling to LAT-1, emodepside activates Gαq and PLC-β (ibid.). The product of the PLC activity, IP3 stimulates release of Ca2+ from intracellular stores, known to be important for α-LTX activity in mammals (Davletov et al. 1998; Capogna et al. 2003). In addition, the effect of emodepside involves UNC-13, a protein implicated in control of vesicular exocytosis and activated by diacyl glycerol, another product of PLC. It is possible that such different agonists as emodepside and LTXN4C can stimulate similar signalling from LPH orthologues, suggesting that at least part of the α-LTX effect on exocytosis is due to LPH signal transduction. Is LPH involved only in one type of signalling, to Ca2+ stores? In fact, α-LTXN4C, acting via LPH, can activate Ca2+ and inhibit K+ channels in pancreatic β-cells (Lajus and Lang 2006), raising the possibility that, similar to many other GPCRs, LPH may be linked to ion channels. In addition, in endocrine cells, α-LTXN4C triggers Ca2+e-independent release of stored calcium and also activates PKC (Liu et al. 2005; Bittner et al. 2005). Thus, α-LTX can both provide an exocytotic stimulus (by releasing stored Ca2+) and sensitise the secretory apparatus to it (by activating PKC). 4.4.3. PTPσ Only LTX binding to PTPσ1, but not to PTPσ2, leads to secretory response in β-cells (Lajus and Lang 2006). This indicates that LTX apparently does not evoke any signalling through PTPσ, which probably simply aids toxin pore formation. Indeed, the multimeric toxin must induce the dimerisation of PTPσ, leading to reciprocal inhibition of the catalytic domains (Tonks 2006). Furthermore, while all three receptors are found naturally occurring in pancreatic β-cells, the distribution of PTPσ does not correlate with the endogenous sensitivity of these cells to α-LTX (Lang et al. 1998; Lajus and Lang 2006). 4.4.4. α-LTX mutants As α-LTXN4C (see 2.3) does not form pores, it probably stimulates exocytosis by receptor mediated signalling. Therefore, the activity of α-LTXN4C has been investigated in Ca2+-dependent and Ca2+-independent exocytosis from neurons and Ca2+-dependent exocytosis from neuroendocrine cells. In Ca2+-free media, the mutant toxin does not stimulate substantial exocytosis in neurons (Ashton et al. 2001; Volynski et al. 2003; Capogna et al. 2003). This strongly indicates that Ca2+-independent exocytosis, so characteristic of wild type α-LTX, requires more than receptor activation. However, α-LTXN4C, strongly stimulates transmitter release from neurons in the presence of Ca2+e, presumably due to its ability to activate LPH1 (Ashton et al. 2001; Capogna et al. 2003; Volynski et al. 2003). The specific details of how receptor activation triggers exocytosis remain to be established, but it is clear that thapsigargin-sensitive release of Ca2+i plays a pivotal role (Ashton et al. 2001; Capogna et al. 2003). α-LTXN4C is also able to stimulate Ca2+-dependent exocytosis from endocrine cells: it is active in chromaffin cells in the presence of Ca2+ or Sr2+ (Volynski et al. 2003) and in pancreatic β-cells (Liu et al. 2005; Lajus and Lang 2006). On the other hand, bacterially expressed α-LTXN4C appears unable to stimulate Ca2+-dependent exocytosis from PC12 cells (Li et al. 2005), but this may be due to mutant’s misfolding or by specific characteristics of the PC12 cell line used. 4.4.5. Receptor knockouts The genes for all three α-LTX receptors have been knocked out in mice, and these mutations are not lethal. NRX Iα knockout mice show no obvious behavioural phenotype (Geppert et al. 1998). LPH1 knockout causes social problems in mice (Tobaben et al. 2002), consistent with LPH1 involvement in schizophrenia (Chen and Chen 2005). PTPσ knockout leads to developmental abnormalities in the nervous system and outside it (Meathrel et al. 2002; Batt et al. 2002). In mice lacking the NRX Iα gene, Ca2+-dependent α-LTX binding to brain membranes is inhibited by 60 % (Geppert et al. 1998), although the Ca2+-independent binding seems to be affected as well (ibid.). LPH1 knockout leads to the loss of 75% of Ca2+-independent binding of α-LTX but also affects the Ca2+-dependent binding (Tobaben et al. 2002). The NRX-LPH1 double knockout still binds about 25% of α-LTX compared to wild type mice, both in the presence and absence of Ca2+ (ibid.). Ca2+-dependent release of glutamate induced by wild-type α-LTX in synaptosomes from the NRX Iα, LPH1 and NRX Iα -LPH1 knockout mice is similarly inhibited, while Ca2+-independent secretion, is most grossly affected in the LPH1 single knockout, but not abolished. Surprisingly, the inactivation of both LPH1 and NRX Iα is less detrimental for the toxin-stimulated release than the LPH1 knockout alone (ibid.). These data suggest that the two α-LTX receptors, NRX Iα and LPH1, may functionally interact (Sudhof 2001), e.g. by reciprocally influencing each other’s expression or synaptic delivery and, thus, altering the actions of α-LTX. The removal of both NRX Iα and LPH1 from synaptic cleft may allow the pore-forming toxin to access PTPσ more freely, with subsequent membrane insertion and Ca2+-independent effects. It would be interesting to test non-pore-forming α-LTX mutants on neuronal preparations from NRX Iα, LPH1 and PTPσ knockout mice. 5. Overview of mechanisms α-LTX causes Ca2+e-dependent and -independent release of neurotransmitters (Figure 6
All α-LTX actions in biological systems require receptors, which provide binding sites for the toxin on the cell surface. Once the toxin is bound, part of its Ca2+-dependent action is due to pore formation and influx of Ca2+. This mechanism triggers the release of both readily releasable and reserve pools of vesicles (Ashton et al. 2001). Another action is based on receptor-mediated signalling, which involves stimulation of PLC, production of IP3 and diacyl glycerol, with respective release of stored Ca2+ and activation of PKC. This mechanism, most likely mediated by LPH1, affects readily releasable vesicles only. Both the pore- and receptor-mediated signals can be amplified by the release of Ca2+i and influx of Ca2+e, producing Ca2+ waves. Mitochondria can contribute to the increase in [Ca2+]i. The pore-mediated component of the Ca2+-dependent action can be blocked by La3+, whereas the receptor-mediated action cannot (Ashton et al. 2001; Capogna et al. 2003). In the absence of Ca2+e, α-LTX only binds to LPH1 and PTPσ. Ca2+-independent exocytosis requires the presence of Mg2+ and toxin insertion into the plasma membrane, but these conditions also induce formation of α-LTX channels. Influx of Na+ and efflux of K+ through these channels and associated efflux of small molecules and influx/efflux of water may cause secretion. In addition, transmitter release can be caused by membrane perturbation or direct interaction with secretory machinery. Some secretion may be non-vesicular. Receptor-mediated signalling can cause the activation of PKC in some cells. However, Ca2+-independent release is blocked by La3+, indicating that toxin pores play a crucial role in this release. Finally, although α-LTX receptors (at least LPH1) can transduce a signal, it is obvious that this signalling cannot explain all the effects of α-LTX. So, while the use of the toxin has brought about the discovery of neuronal cell adhesion protein families (NRX and LPH) and new knowledge about PTPσ, the toxin’s effect in the absence of Ca2+e remains unclear, and its study may throw light onto the very basic mechanisms of exocytosis and different levels of its regulation. Contributor Information Yuri A. Ushkaryov, Division of Cell and Molecular Biology, Imperial College London, London, SW7 2AY, UK, Tel. +44 (0)20 7594 5237; Fax: +44 (0)20 7594 5207; e-mail: y.ushkaryov/at/imperial.ac.uk; Alexis Rohou, Division of Cell and Molecular Biology, Imperial College London, London, SW7 2AY, UK, Tel. +44 (0)20 7594 5237; Fax: +44 (0)20 7594 5207; e-mail: alexis.rohou/at/imperial.ac.uk; Shuzo Sugita, Division of Cellular & Molecular Biology, Toronto Western Research Institute, Toronto, Ontario, M5T 2S8, Canada, Tel. +1 416 603 5800; Fax: +1 416 603 5745; e-mail: ssugita/at/uhnres.utoronto.ca; 6. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||
Nature. 1970 Feb 21; 225(5234):701-3.
[Nature. 1970]J Cell Biol. 1976 Mar; 68(3):462-79.
[J Cell Biol. 1976]Annu Rev Neurosci. 1987; 10():633-93.
[Annu Rev Neurosci. 1987]J Cell Biol. 1980 Oct; 87(1):297-303.
[J Cell Biol. 1980]Comp Biochem Physiol B Biochem Mol Biol. 2006 Nov-Dec; 145(3-4):350-7.
[Comp Biochem Physiol B Biochem Mol Biol. 2006]Toxicon. 1998 Nov; 36(11):1693-701.
[Toxicon. 1998]Pharmacol Ther. 1989; 42(1):115-34.
[Pharmacol Ther. 1989]J Cell Biol. 1976 Mar; 68(3):462-79.
[J Cell Biol. 1976]Proc Natl Acad Sci U S A. 1978 Aug; 75(8):4016-20.
[Proc Natl Acad Sci U S A. 1978]Mol Pharmacol. 1990 Dec; 38(6):917-23.
[Mol Pharmacol. 1990]Nature. 1970 Feb 21; 225(5234):701-3.
[Nature. 1970]J Cell Biol. 1976 Mar; 68(3):462-79.
[J Cell Biol. 1976]Proc Natl Acad Sci U S A. 1978 Aug; 75(8):4016-20.
[Proc Natl Acad Sci U S A. 1978]FEBS Lett. 1978 Jan 15; 85(2):241-4.
[FEBS Lett. 1978]Nature. 1970 Feb 21; 225(5234):701-3.
[Nature. 1970]J Cell Biol. 1976 Mar; 68(3):462-79.
[J Cell Biol. 1976]Science. 1976 Sep 10; 193(4257):1009-11.
[Science. 1976]Nature. 1970 Feb 21; 225(5234):701-3.
[Nature. 1970]Proc Natl Acad Sci U S A. 1979 Feb; 76(2):991-5.
[Proc Natl Acad Sci U S A. 1979]J Cell Biol. 1980 Oct; 87(1):297-303.
[J Cell Biol. 1980]J Neurosci. 2000 Dec 1; 20(23):8685-92.
[J Neurosci. 2000]J Neurophysiol. 1996 Nov; 76(5):3149-58.
[J Neurophysiol. 1996]Nature. 1970 Feb 21; 225(5234):701-3.
[Nature. 1970]J Cell Biol. 1979 Apr; 81(1):163-77.
[J Cell Biol. 1979]Annu Rev Neurosci. 2001; 24():933-62.
[Annu Rev Neurosci. 2001]Toxicon. 2004 Apr; 43(5):527-42.
[Toxicon. 2004]Proc Natl Acad Sci U S A. 1988 Oct; 85(19):7366-70.
[Proc Natl Acad Sci U S A. 1988]EMBO J. 1998 Jul 15; 17(14):3909-20.
[EMBO J. 1998]Neuroscience. 2000; 101(3):793-802.
[Neuroscience. 2000]Nature. 1980 Feb 21; 283(5749):774-6.
[Nature. 1980]J Physiol. 1997 Aug 1; 502 ( Pt 3)():481-96.
[J Physiol. 1997]Proc Natl Acad Sci U S A. 1979 Feb; 76(2):991-5.
[Proc Natl Acad Sci U S A. 1979]Mol Pharmacol. 1990 Dec; 38(6):917-23.
[Mol Pharmacol. 1990]FEBS Lett. 1978 Jan 15; 85(2):241-4.
[FEBS Lett. 1978]J Neurochem. 1998 Dec; 71(6):2421-30.
[J Neurochem. 1998]J Neurosci. 2000 Dec 1; 20(23):8685-92.
[J Neurosci. 2000]Nature. 1970 Feb 21; 225(5234):701-3.
[Nature. 1970]J Cell Biol. 1980 Oct; 87(1):297-303.
[J Cell Biol. 1980]J Neurocytol. 1983 Jun; 12(3):517-31.
[J Neurocytol. 1983]J Cell Biol. 1979 Apr; 81(1):163-77.
[J Cell Biol. 1979]J Gen Physiol. 1986 Jul; 88(1):59-81.
[J Gen Physiol. 1986]Neuron. 1997 Jul; 19(1):139-50.
[Neuron. 1997]Biochem Biophys Res Commun. 1984 Jun 15; 121(2):538-44.
[Biochem Biophys Res Commun. 1984]EMBO J. 1998 Jul 15; 17(14):3909-20.
[EMBO J. 1998]J Biol Chem. 2001 Nov 30; 276(48):44695-703.
[J Biol Chem. 2001]J Neurosci. 2003 May 15; 23(10):4044-53.
[J Neurosci. 2003]FEBS Lett. 1990 Sep 17; 270(1-2):127-31.
[FEBS Lett. 1990]Toxicon. 1990; 28(3):341-6.
[Toxicon. 1990]Comp Biochem Physiol B Biochem Mol Biol. 2006 Nov-Dec; 145(3-4):350-7.
[Comp Biochem Physiol B Biochem Mol Biol. 2006]FEBS Lett. 1999 Jan 8; 442(1):25-8.
[FEBS Lett. 1999]EMBO J. 1998 Nov 2; 17(21):6188-99.
[EMBO J. 1998]Eur J Biochem. 1995 Jun 15; 230(3):854-9.
[Eur J Biochem. 1995]Trends Biochem Sci. 1999 Aug; 24(8):311-6.
[Trends Biochem Sci. 1999]EMBO J. 1998 Nov 2; 17(21):6188-99.
[EMBO J. 1998]Nat Struct Biol. 2000 Jan; 7(1):48-53.
[Nat Struct Biol. 2000]Nat Struct Biol. 2000 Jan; 7(1):48-53.
[Nat Struct Biol. 2000]Nat Struct Biol. 2000 Jan; 7(1):48-53.
[Nat Struct Biol. 2000]EMBO J. 2002 Dec 2; 21(23):6387-96.
[EMBO J. 2002]J Struct Biol. 2001 May-Jun; 134(2-3):117-31.
[J Struct Biol. 2001]Nat Struct Biol. 2000 Jan; 7(1):48-53.
[Nat Struct Biol. 2000]J Biol Chem. 2001 Nov 30; 276(48):44695-703.
[J Biol Chem. 2001]Bioorg Khim. 1991 Aug; 17(8):1021-6.
[Bioorg Khim. 1991]J Membr Biol. 1987; 95(1):55-62.
[J Membr Biol. 1987]Biochim Biophys Acta. 1992 Nov 23; 1112(1):124-8.
[Biochim Biophys Acta. 1992]Neuroscience. 1994 Jul; 61(1):179-89.
[Neuroscience. 1994]Eur J Neurosci. 2000 Nov; 12(11):3953-62.
[Eur J Neurosci. 2000]EMBO J. 1998 Nov 2; 17(21):6188-99.
[EMBO J. 1998]FEBS Lett. 1999 Jan 8; 442(1):25-8.
[FEBS Lett. 1999]J Biol Chem. 2003 Aug 15; 278(33):31058-66.
[J Biol Chem. 2003]J Neurosci. 2005 Nov 2; 25(44):10188-97.
[J Neurosci. 2005]Biochimie. 2000 May; 82(5):453-68.
[Biochimie. 2000]Nat Struct Biol. 2000 Jan; 7(1):48-53.
[Nat Struct Biol. 2000]Proc Natl Acad Sci U S A. 1979 Feb; 76(2):991-5.
[Proc Natl Acad Sci U S A. 1979]J Biol Chem. 2001 Nov 30; 276(48):44695-703.
[J Biol Chem. 2001]EMBO J. 1998 Nov 2; 17(21):6188-99.
[EMBO J. 1998]J Biol Chem. 2003 Aug 15; 278(33):31058-66.
[J Biol Chem. 2003]J Biol Chem. 2001 Nov 30; 276(48):44695-703.
[J Biol Chem. 2001]Science. 1976 Sep 10; 193(4257):1009-11.
[Science. 1976]EMBO J. 1986 Oct; 5(10):2643-8.
[EMBO J. 1986]Mol Pharmacol. 2000 Mar; 57(3):519-28.
[Mol Pharmacol. 2000]Eur J Neurosci. 2000 Nov; 12(11):3953-62.
[Eur J Neurosci. 2000]J Biol Chem. 2000 Dec 29; 275(52):41175-83.
[J Biol Chem. 2000]EMBO J. 1998 Nov 2; 17(21):6188-99.
[EMBO J. 1998]J Neurosci. 2005 Nov 2; 25(44):10188-97.
[J Neurosci. 2005]Nat Struct Biol. 2000 Jan; 7(1):48-53.
[Nat Struct Biol. 2000]Toxicon. 1992 Sep; 30(9):1059-64.
[Toxicon. 1992]Neuroscience. 2000; 101(3):793-802.
[Neuroscience. 2000]Biochim Biophys Acta. 1987 Jun 30; 900(2):295-9.
[Biochim Biophys Acta. 1987]FEBS Lett. 1990 Jun 18; 266(1-2):99-101.
[FEBS Lett. 1990]Science. 1976 Sep 10; 193(4257):1009-11.
[Science. 1976]Neuroscience. 2000; 101(3):793-802.
[Neuroscience. 2000]J Biol Chem. 2000 Dec 29; 275(52):41175-83.
[J Biol Chem. 2000]Toxicon. 1995 Apr; 33(4):483-9.
[Toxicon. 1995]Eur J Biochem. 1995 May 15; 230(1):322-8.
[Eur J Biochem. 1995]Biochimie. 2000 May; 82(5):453-68.
[Biochimie. 2000]J Biol Chem. 2000 Dec 29; 275(52):41175-83.
[J Biol Chem. 2000]J Neurosci. 2005 Nov 2; 25(44):10188-97.
[J Neurosci. 2005]J Neurosci. 2005 Nov 2; 25(44):10188-97.
[J Neurosci. 2005]Science. 1976 Sep 10; 193(4257):1009-11.
[Science. 1976]Biofizika. 1982 Jan-Feb; 27(1):72-5.
[Biofizika. 1982]Biochim Biophys Acta. 1986 Nov 6; 862(1):185-98.
[Biochim Biophys Acta. 1986]Biochim Biophys Acta. 1986 Nov 6; 862(1):185-98.
[Biochim Biophys Acta. 1986]Biochim Biophys Acta. 1989 Jan 30; 978(2):179-84.
[Biochim Biophys Acta. 1989]Biochim Biophys Acta. 1992 Nov 23; 1112(1):124-8.
[Biochim Biophys Acta. 1992]J Neurosci. 2005 Nov 2; 25(44):10188-97.
[J Neurosci. 2005]J Membr Biol. 1994 Feb; 138(1):91-102.
[J Membr Biol. 1994]Endocrinology. 1999 Jul; 140(7):3025-33.
[Endocrinology. 1999]Proc Natl Acad Sci U S A. 1982 Dec; 79(24):7924-8.
[Proc Natl Acad Sci U S A. 1982]Proc Natl Acad Sci U S A. 1984 Jan; 81(2):620-4.
[Proc Natl Acad Sci U S A. 1984]Nature. 1980 Feb 21; 283(5749):774-6.
[Nature. 1980]Pflugers Arch. 1996 Oct; 432(6):1039-46.
[Pflugers Arch. 1996]J Biol Chem. 2000 Dec 29; 275(52):41175-83.
[J Biol Chem. 2000]Endocrinology. 1999 Jul; 140(7):3025-33.
[Endocrinology. 1999]J Neurosci. 2000 Dec 1; 20(23):8685-92.
[J Neurosci. 2000]Traffic. 2005 Sep; 6(9):756-65.
[Traffic. 2005]Proc Natl Acad Sci U S A. 1982 Dec; 79(24):7924-8.
[Proc Natl Acad Sci U S A. 1982]J Biol Chem. 2006 Mar 3; 281(9):5522-31.
[J Biol Chem. 2006]Biofizika. 1982 Jan-Feb; 27(1):72-5.
[Biofizika. 1982]Biochim Biophys Acta. 1986 Nov 6; 862(1):185-98.
[Biochim Biophys Acta. 1986]Biochem Biophys Res Commun. 1986 Jan 14; 134(1):320-5.
[Biochem Biophys Res Commun. 1986]Neuroscience. 1994 Jul; 61(1):179-89.
[Neuroscience. 1994]J Membr Biol. 1994 Feb; 138(1):91-102.
[J Membr Biol. 1994]Eur J Biochem. 1979 Dec 17; 102(2):337-44.
[Eur J Biochem. 1979]Proc Natl Acad Sci U S A. 1982 Dec; 79(24):7924-8.
[Proc Natl Acad Sci U S A. 1982]EMBO J. 1986 Oct; 5(10):2643-8.
[EMBO J. 1986]J Neurochem. 1990 Dec; 55(6):2039-47.
[J Neurochem. 1990]J Neurochem. 1993 Sep; 61(3):818-25.
[J Neurochem. 1993]J Neurosci. 2000 Dec 1; 20(23):8685-92.
[J Neurosci. 2000]Brain Res. 2003 Nov 28; 992(1):30-42.
[Brain Res. 2003]J Neurochem. 1993 Sep; 61(3):818-25.
[J Neurochem. 1993]Brain Res. 1981 Jan 5; 204(1):204-8.
[Brain Res. 1981]FEBS Lett. 1994 Sep 5; 351(2):267-70.
[FEBS Lett. 1994]Biochem Biophys Res Commun. 1986 Jan 14; 134(1):320-5.
[Biochem Biophys Res Commun. 1986]Biochim Biophys Acta. 1992 Nov 23; 1112(1):124-8.
[Biochim Biophys Acta. 1992]Science. 1976 Sep 10; 193(4257):1009-11.
[Science. 1976]Eur J Neurosci. 2000 Nov; 12(11):3953-62.
[Eur J Neurosci. 2000]J Gen Physiol. 1994 Sep; 104(3):425-47.
[J Gen Physiol. 1994]EMBO J. 1986 Oct; 5(10):2643-8.
[EMBO J. 1986]Biochim Biophys Acta. 1992 Nov 23; 1112(1):124-8.
[Biochim Biophys Acta. 1992]Toxicon. 1992 Sep; 30(9):1059-64.
[Toxicon. 1992]Mol Pharmacol. 2000 Mar; 57(3):519-28.
[Mol Pharmacol. 2000]Eur J Neurosci. 2000 Nov; 12(11):3953-62.
[Eur J Neurosci. 2000]Biochim Biophys Acta. 1986 Nov 6; 862(1):185-98.
[Biochim Biophys Acta. 1986]J Membr Biol. 1994 Feb; 138(1):91-102.
[J Membr Biol. 1994]Mol Pharmacol. 2000 Mar; 57(3):519-28.
[Mol Pharmacol. 2000]Neuroscience. 1994 Jul; 61(1):179-89.
[Neuroscience. 1994]EMBO J. 1998 Jul 15; 17(14):3909-20.
[EMBO J. 1998]J Membr Biol. 1987; 95(1):55-62.
[J Membr Biol. 1987]Biochim Biophys Acta. 1992 Nov 23; 1112(1):124-8.
[Biochim Biophys Acta. 1992]Neuroscience. 1994 Jul; 61(1):179-89.
[Neuroscience. 1994]Eur J Neurosci. 2000 Nov; 12(11):3953-62.
[Eur J Neurosci. 2000]Bioorg Khim. 1991 Aug; 17(8):1021-6.
[Bioorg Khim. 1991]Neuroscience. 1994 Jul; 61(1):179-89.
[Neuroscience. 1994]Science. 1976 Sep 10; 193(4257):1009-11.
[Science. 1976]Biochem Biophys Res Commun. 1986 Jan 14; 134(1):320-5.
[Biochem Biophys Res Commun. 1986]J Membr Biol. 1994 Feb; 138(1):91-102.
[J Membr Biol. 1994]Biochim Biophys Acta. 1992 Nov 23; 1112(1):124-8.
[Biochim Biophys Acta. 1992]Biochim Biophys Acta. 1986 Nov 6; 862(1):185-98.
[Biochim Biophys Acta. 1986]J Neurochem. 1989 May; 52(5):1590-7.
[J Neurochem. 1989]Biochimie. 2000 May; 82(5):453-68.
[Biochimie. 2000]J Neurochem. 1989 May; 52(5):1590-7.
[J Neurochem. 1989]J Membr Biol. 1994 Feb; 138(1):91-102.
[J Membr Biol. 1994]Eur J Neurosci. 2000 Nov; 12(11):3953-62.
[Eur J Neurosci. 2000]J Neurosci. 2003 May 15; 23(10):4044-53.
[J Neurosci. 2003]J Neurochem. 1989 May; 52(5):1590-7.
[J Neurochem. 1989]Am J Physiol. 1987 Sep; 253(3 Pt 1):C469-76.
[Am J Physiol. 1987]Biochim Biophys Acta. 1992 Nov 23; 1112(1):124-8.
[Biochim Biophys Acta. 1992]Nat Struct Biol. 2000 Jan; 7(1):48-53.
[Nat Struct Biol. 2000]EMBO J. 1998 Jul 15; 17(14):3909-20.
[EMBO J. 1998]Philos Trans R Soc Lond B Biol Sci. 1999 Feb 28; 354(1381):379-86.
[Philos Trans R Soc Lond B Biol Sci. 1999]J Biol Chem. 2000 Dec 29; 275(52):41175-83.
[J Biol Chem. 2000]J Neurochem. 1990 Dec; 55(6):2039-47.
[J Neurochem. 1990]J Neurochem. 1993 Mar; 60(3):1065-72.
[J Neurochem. 1993]EMBO J. 1998 Jul 15; 17(14):3909-20.
[EMBO J. 1998]J Neurosci. 2000 Dec 1; 20(23):8685-92.
[J Neurosci. 2000]J Physiol. 1997 Aug 1; 502 ( Pt 3)():481-96.
[J Physiol. 1997]J Biol Chem. 2000 Aug 18; 275(33):25351-7.
[J Biol Chem. 2000]EMBO J. 1990 Jun; 9(6):2023-7.
[EMBO J. 1990]J Biol Chem. 1996 Sep 20; 271(38):23239-45.
[J Biol Chem. 1996]Biochem Biophys Res Commun. 1996 Oct 23; 227(3):868-75.
[Biochem Biophys Res Commun. 1996]J Biol Chem. 2002 Nov 29; 277(48):46518-26.
[J Biol Chem. 2002]EMBO J. 1990 Jun; 9(6):2023-7.
[EMBO J. 1990]Science. 1992 Jul 3; 257(5066):50-6.
[Science. 1992]Science. 1992 Jul 3; 257(5066):50-6.
[Science. 1992]Proc Natl Acad Sci U S A. 1993 Jul 15; 90(14):6410-4.
[Proc Natl Acad Sci U S A. 1993]Neuron. 1995 Mar; 14(3):497-507.
[Neuron. 1995]J Neurochem. 1998 Oct; 71(4):1339-47.
[J Neurochem. 1998]Trends Genet. 1998 Jan; 14(1):20-6.
[Trends Genet. 1998]Science. 1992 Jul 3; 257(5066):50-6.
[Science. 1992]J Biol Chem. 1994 Apr 22; 269(16):11987-92.
[J Biol Chem. 1994]Science. 1992 Jul 3; 257(5066):50-6.
[Science. 1992]Biochem Biophys Res Commun. 2002 Oct 18; 298(1):151-5.
[Biochem Biophys Res Commun. 2002]Neuron. 1995 Mar; 14(3):497-507.
[Neuron. 1995]Nat Neurosci. 2003 Jul; 6(7):708-16.
[Nat Neurosci. 2003]Proc Natl Acad Sci U S A. 1999 Feb 2; 96(3):1100-5.
[Proc Natl Acad Sci U S A. 1999]EMBO J. 1990 Jun; 9(6):2023-7.
[EMBO J. 1990]J Biol Chem. 1993 Jan 25; 268(3):1860-7.
[J Biol Chem. 1993]J Biol Chem. 1995 Oct 13; 270(41):23903-5.
[J Biol Chem. 1995]J Biol Chem. 1995 Oct 13; 270(41):23903-5.
[J Biol Chem. 1995]Neuron. 1999 Mar; 22(3):489-96.
[Neuron. 1999]EMBO J. 1990 Jun; 9(6):2023-7.
[EMBO J. 1990]J Neurosci. 2005 Nov 2; 25(44):10188-97.
[J Neurosci. 2005]J Biol Chem. 1993 Jan 25; 268(3):1860-7.
[J Biol Chem. 1993]J Neurosci. 1996 Jul 15; 16(14):4360-9.
[J Neurosci. 1996]J Biol Chem. 1998 Dec 25; 273(52):34716-23.
[J Biol Chem. 1998]Trends Genet. 1998 Jan; 14(1):20-6.
[Trends Genet. 1998]Cell. 1995 May 5; 81(3):435-43.
[Cell. 1995]J Biol Chem. 1996 Feb 2; 271(5):2676-82.
[J Biol Chem. 1996]J Biol Chem. 1997 Oct 10; 272(41):26032-9.
[J Biol Chem. 1997]Neuron. 2005 Oct 20; 48(2):229-36.
[Neuron. 2005]Proc Natl Acad Sci U S A. 1999 Feb 2; 96(3):1100-5.
[Proc Natl Acad Sci U S A. 1999]J Neurosci. 1996 Apr 15; 16(8):2488-94.
[J Neurosci. 1996]J Biol Chem. 2000 Dec 22; 275(51):39803-6.
[J Biol Chem. 2000]Science. 2000 Feb 4; 287(5454):864-9.
[Science. 2000]J Neurosci. 2005 Apr 27; 25(17):4330-42.
[J Neurosci. 2005]Nature. 2003 Jun 26; 423(6943):939-48.
[Nature. 2003]J Biol Chem. 1996 Sep 20; 271(38):23239-45.
[J Biol Chem. 1996]J Biol Chem. 1997 Aug 22; 272(34):21504-8.
[J Biol Chem. 1997]Biochem Biophys Res Commun. 1996 Oct 23; 227(3):868-75.
[Biochem Biophys Res Commun. 1996]Neuron. 1997 Jun; 18(6):925-37.
[Neuron. 1997]Biochemistry. 1991 Sep 24; 30(38):9143-53.
[Biochemistry. 1991]J Neurosci. 2004 Mar 3; 24(9):2191-201.
[J Neurosci. 2004]Genome Biol. 2001; 2(12):REVIEWS3013.
[Genome Biol. 2001]J Recept Signal Transduct Res. 2000 May-Aug; 20(2-3):119-31.
[J Recept Signal Transduct Res. 2000]Trends Biochem Sci. 2000 Jun; 25(6):284-9.
[Trends Biochem Sci. 2000]Mol Pharmacol. 2005 May; 67(5):1414-25.
[Mol Pharmacol. 2005]FEBS Lett. 1999 Jan 29; 443(3):348-52.
[FEBS Lett. 1999]J Biol Chem. 1999 Feb 26; 274(9):5491-8.
[J Biol Chem. 1999]J Biol Chem. 1998 Dec 4; 273(49):32715-24.
[J Biol Chem. 1998]J Immunol. 1996 Dec 15; 157(12):5438-47.
[J Immunol. 1996]Neuron. 1997 Jun; 18(6):925-37.
[Neuron. 1997]EMBO J. 2004 Nov 10; 23(22):4423-33.
[EMBO J. 2004]J Recept Signal Transduct Res. 2000 May-Aug; 20(2-3):119-31.
[J Recept Signal Transduct Res. 2000]Trends Biochem Sci. 2000 Jun; 25(6):284-9.
[Trends Biochem Sci. 2000]EMBO J. 2004 Nov 10; 23(22):4423-33.
[EMBO J. 2004]J Biol Chem. 2001 Nov 30; 276(48):44695-703.
[J Biol Chem. 2001]J Neurosci. 2003 May 15; 23(10):4044-53.
[J Neurosci. 2003]J Biol Chem. 1998 Dec 4; 273(49):32715-24.
[J Biol Chem. 1998]J Biol Chem. 1999 Feb 26; 274(9):5491-8.
[J Biol Chem. 1999]FEBS Lett. 1999 Jan 29; 443(3):348-52.
[FEBS Lett. 1999]Science. 1992 Jul 3; 257(5066):50-6.
[Science. 1992]Biochem Biophys Res Commun. 2002 Oct 18; 298(1):151-5.
[Biochem Biophys Res Commun. 2002]J Biol Chem. 2000 Dec 29; 275(52):41175-83.
[J Biol Chem. 2000]J Biol Chem. 1999 Feb 26; 274(9):5491-8.
[J Biol Chem. 1999]J Biol Chem. 1999 Feb 5; 274(6):3590-6.
[J Biol Chem. 1999]EMBO J. 2004 Nov 10; 23(22):4423-33.
[EMBO J. 2004]J Biol Chem. 2002 Feb 22; 277(8):6359-65.
[J Biol Chem. 2002]Biochem Biophys Res Commun. 1996 Oct 23; 227(3):868-75.
[Biochem Biophys Res Commun. 1996]J Biol Chem. 2002 Sep 27; 277(39):35887-95.
[J Biol Chem. 2002]Nat Rev Mol Cell Biol. 2006 Nov; 7(11):833-46.
[Nat Rev Mol Cell Biol. 2006]J Biol Chem. 1993 Nov 25; 268(33):24880-6.
[J Biol Chem. 1993]J Cell Biol. 1997 Aug 11; 138(3):681-96.
[J Cell Biol. 1997]J Biol Chem. 1994 Sep 23; 269(38):23632-41.
[J Biol Chem. 1994]Cell Signal. 2006 Sep; 18(9):1515-27.
[Cell Signal. 2006]J Biol Chem. 1993 Nov 25; 268(33):24880-6.
[J Biol Chem. 1993]Proc Natl Acad Sci U S A. 1995 Dec 5; 92(25):11686-90.
[Proc Natl Acad Sci U S A. 1995]J Biol Chem. 2002 Sep 27; 277(39):35887-95.
[J Biol Chem. 2002]J Cell Biochem. 2006 Aug 15; 98(6):1552-9.
[J Cell Biochem. 2006]J Neurosci. 2002 Jul 1; 22(13):5481-91.
[J Neurosci. 2002]Mol Cell Neurosci. 2003 Aug; 23(4):681-92.
[Mol Cell Neurosci. 2003]J Neurosci Res. 2002 Oct 1; 70(1):24-35.
[J Neurosci Res. 2002]Mol Cell Biol. 2007 Jan; 27(1):208-19.
[Mol Cell Biol. 2007]Mol Cell Neurosci. 2003 Jan; 22(1):37-48.
[Mol Cell Neurosci. 2003]FEBS J. 2006 Oct; 273(20):4668-81.
[FEBS J. 2006]Neuron. 1999 Mar; 22(3):489-96.
[Neuron. 1999]J Biol Chem. 2000 Dec 29; 275(52):41175-83.
[J Biol Chem. 2000]Mol Pharmacol. 2000 Mar; 57(3):519-28.
[Mol Pharmacol. 2000]EMBO J. 1998 Jul 15; 17(14):3909-20.
[EMBO J. 1998]J Biol Chem. 2001 Nov 30; 276(48):44695-703.
[J Biol Chem. 2001]EMBO J. 2004 Nov 10; 23(22):4423-33.
[EMBO J. 2004]J Biol Chem. 2003 Aug 15; 278(33):31058-66.
[J Biol Chem. 2003]J Neurosci. 2003 May 15; 23(10):4044-53.
[J Neurosci. 2003]Biochem J. 2004 Feb 15; 378(Pt 1):185-91.
[Biochem J. 2004]Curr Biol. 2004 Aug 10; 14(15):1374-9.
[Curr Biol. 2004]EMBO J. 1998 Jul 15; 17(14):3909-20.
[EMBO J. 1998]J Neurosci. 2003 May 15; 23(10):4044-53.
[J Neurosci. 2003]J Cell Biochem. 2006 Aug 15; 98(6):1552-9.
[J Cell Biochem. 2006]Traffic. 2005 Sep; 6(9):756-65.
[Traffic. 2005]J Cell Biochem. 2006 Aug 15; 98(6):1552-9.
[J Cell Biochem. 2006]Nat Rev Mol Cell Biol. 2006 Nov; 7(11):833-46.
[Nat Rev Mol Cell Biol. 2006]EMBO J. 1998 Feb 2; 17(3):648-57.
[EMBO J. 1998]J Biol Chem. 2001 Nov 30; 276(48):44695-703.
[J Biol Chem. 2001]J Biol Chem. 2003 Aug 15; 278(33):31058-66.
[J Biol Chem. 2003]J Neurosci. 2003 May 15; 23(10):4044-53.
[J Neurosci. 2003]J Biol Chem. 2003 Aug 15; 278(33):31058-66.
[J Biol Chem. 2003]Traffic. 2005 Sep; 6(9):756-65.
[Traffic. 2005]J Cell Biochem. 2006 Aug 15; 98(6):1552-9.
[J Cell Biochem. 2006]J Neurosci. 2005 Nov 2; 25(44):10188-97.
[J Neurosci. 2005]J Biol Chem. 1998 Jan 16; 273(3):1705-10.
[J Biol Chem. 1998]J Biol Chem. 2002 Feb 22; 277(8):6359-65.
[J Biol Chem. 2002]Neuropsychopharmacology. 2005 Feb; 30(2):268-77.
[Neuropsychopharmacology. 2005]J Neurosci Res. 2002 Oct 1; 70(1):24-35.
[J Neurosci Res. 2002]Mol Endocrinol. 2002 Jan; 16(1):155-69.
[Mol Endocrinol. 2002]J Biol Chem. 1998 Jan 16; 273(3):1705-10.
[J Biol Chem. 1998]J Biol Chem. 2002 Feb 22; 277(8):6359-65.
[J Biol Chem. 2002]Annu Rev Neurosci. 2001; 24():933-62.
[Annu Rev Neurosci. 2001]J Biol Chem. 2001 Nov 30; 276(48):44695-703.
[J Biol Chem. 2001]J Neurosci. 2003 May 15; 23(10):4044-53.
[J Neurosci. 2003]Nat Struct Biol. 2000 Jan; 7(1):48-53.
[Nat Struct Biol. 2000]Nat Struct Biol. 2000 Jan; 7(1):48-53.
[Nat Struct Biol. 2000]Science. 2005 Aug 5; 309(5736):897-903.
[Science. 2005]J Mol Biol. 2005 Jan 21; 345(3):427-31.
[J Mol Biol. 2005]J Comput Chem. 2004 Oct; 25(13):1605-12.
[J Comput Chem. 2004]EMBO J. 2004 Nov 10; 23(22):4423-33.
[EMBO J. 2004]